Classification Accuracy of Transcranial Magnetic Stimulation for the Diagnosis of Neurodegenerative Dementias. Issue 3 (23rd January 2020)

• Record Type: Journal Article
• Authors: Benussi, Alberto; Grassi, Mario; Palluzzi, Fernando; Koch, Giacomo; Di Lazzaro, Vincenzo; Nardone, Raffaele; Cantoni, Valentina; Dell'Era, Valentina; Premi, Enrico; Martorana, Alessandro; di Lorenzo, Francesco; Bonnì, Sonia; Ranieri, Federico; Capone, Fioravante; Musumeci, Gabriella; Cotelli, Maria Sofia; Padovani, Alessandro; Borroni, Barbara
• Is Part Of: Annals of neurology. Volume 87:Issue 3(2020)
• Page Start: 394
• Page End: 404
• Publication Date: 2020-01-23
• Subjects: Neurology -- Periodicals; Pediatric neurology -- Periodicals; Nervous system -- Surgery -- Periodicals; 616.8
• DOI: 10.1002/ana.25677
• Languages: English
• ISSNs: 0364-5134

Abstract

Abstract : Objective: Transcranial magnetic stimulation (TMS) has been suggested as a reliable, noninvasive, and inexpensive tool for the diagnosis of neurodegenerative dementias. In this study, we assessed the classification performance of TMS parameters in the differential diagnosis of common neurodegenerative disorders, including Alzheimer disease (AD), dementia with Lewy bodies (DLB), and frontotemporal dementia (FTD). Methods: We performed a multicenter study enrolling patients referred to 4 dementia centers in Italy, in accordance with the Standards for Reporting of Diagnostic Accuracy. All patients underwent TMS assessment at recruitment (index test), with application of reference clinical criteria, to predict different neurodegenerative disorders. The investigators who performed the index test were masked to the results of the reference test and all other investigations. We trained and tested a random forest classifier using 5‐fold cross‐validation. The primary outcome measures were the classification accuracy, precision, recall, and F1 score of TMS in differentiating each neurodegenerative disorder. Results: A total of 694 participants were included, namely 273 patients diagnosed as AD, 67 as DLB, and 207 as FTD, and 147 healthy controls (HC). A series of 3 binary classifiers was employed, and the prediction model exhibited high classification accuracy (ranging from 0.89 to 0.92), high precision (0.86–0.92), high recall (0.93–0.98), and high F1 scores (0.89–0.95) in differentiating each neurodegenerative disorder. Interpretation: TMS is a noninvasive procedure that reliably and selectively distinguishes AD, DLB, FTD, and HC, representing a useful additional screening tool to be used in clinical practice. Ann Neurol 2020;87:394–404